Innova Captab DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024


0.76×	0.76×	0.75×	0.73×
0.96×	0.95×	1.06×	0.94×
12.2%	12.1%	13.0%	12.8%
0.95×	0.95×	0.86×	0.82×
1.70×	1.70×	1.65×	1.59×
14.4%	14.2%	14.6%	11.4%
14.0%	14.0%	14.3%	11.4%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

INNOVACAP₹1,051.10

Innova Captab Limited

· Pharma & Health

₹ CrorePeersMOREPENLAB IOLCP FDC SENORES SANOFI ORCHPHARMA GUJTHEM RPGLIFEMcap ₹6,015 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.73	0.75	0.76	0.76
Interest Burden (Pretax/EBIT) ×	0.94	1.06	0.95	0.96
EBIT Margin %	12.81	12.98	12.13	12.21
Asset Turnover ×	0.82	0.86	0.95	0.95
Financial Leverage (Assets/Equity) ×	1.59	1.65	1.70	1.70
ROE (5-step product, year-end total equity) %	11.37	14.61	14.18	14.42
ROE (owners' profit / average owners' equity) %	11.35	14.33	14.03	14.03

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.